Abstract
Lung cancer is the leading cause of cancer death among men and women in the United States with 170,000 deaths per year. This exceeds the sum of the next three leading causes of death due to cancer: breast, colon, and prostate. There are over 1 million deaths worldwide due to lung cancer, making it truly an epidemic. Fewer than 15% achieve a 5-yr survival. The vast majority (85%) present with advanced disease, although stage I patients may have a 5-yr survival approaching 70% (1). 80% of the lung cancers are non-small cell lung cancer (NSCLC; adenocarcinomas, squamous cell, bronchoalveolar and large cell carcinomas) and 20% are small cell lung cancer (SCLC). Cigarette smoking constitutes 80% of the attributable risk and asbestos, radon, other occupational and environmental exposures and genetic factors contribute to the rest. The purpose of this state of the art review is to introduce the molecular genetics of lung cancer for the clinician in this rapidly progressing field. Many of the basic science concepts to follow already are being studied in clinical trials of new chemotherapeutic agents or gene therapy.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Nesbitt, J. C., Putnam, J. B. Jr., Walsh, G. L., Roth, J. A., and Mountain, C. F. (1995) Survival in early-stage lung cancer. Ann. Thorac. Surg. 60, 466ā472.
Miller, J. A. and Jones, O. R. (1930) Primary carcinoma of the lung. Am. Rev. Tuberc. 21, 1ā56.
Ochsner, M. and DeBakey, M. (1939) Symposium on cancer. Primary pulmonary malignancy. Treatment by total pneumonectomy; analyses of 79 collected cases and presentation of 7 personal cases. Surg. Gynecol. Obstet. 68, 435ā451.
Weiss, W., Seidman, H., and Boucot, K. R. (1978) The Philadelphia pulmonary neoplasm research project. Symptoms in occult lung cancer. Chest 73, 57ā61.
Sridhar, K. S., Lobo, C. F., and Altman, R. D. (1998) Digital clubbing and lung cancer. Chest 114, 1535ā1537.
Mountain, C. F. (1997) Revisions in the International System for staging lung cancer. Chest 111, 1710ā1717.
ATS/ERS Statement. (1997) Pretreatment evaluation of non-small-cell lung cancer. Am. J. Respir. Crit. Care Med. 156, 320ā332.
Shaw, G. L., Falk, R. T., Pickle, L. W., Mason, T. J., and Buffler, D. A. (1991) Lung cancer risk associated with cancer in relatives. J. Clin. Epidemiol. 44, 429ā437.
Saraceno, J. and Spivack, S. D. (1999) Strategies for early detection of lung cancer. Clin. Pulm. Med. 6, 66ā72.
Henschke, C. I., McCauley, D. I., Yankelevitz, D. F., Naidich, D. P., McGuinness, G., Miettinen, O. S., et al. (1999) Early lung cancer action project: overall design and findings from baseline screening. Lancet 354, 99ā105.
Kennedy, T. C., Proudfoot, S. P., Franklin, W. A., et al. (1996) Cytopathological analysis of sputum in patients with airflow obstruction and significant smoking histories. Cancer Res. 56, 4673ā4678.
Tockman, M. S. Mulshine, J. L., Piantadosi, S., et al. (1997) Prospective detection of preclinical lung cancer: results from two studies of heterogeneous nuclear ribonucleoprotein A2/B1 overexpression. Clin. Cancer Res. 3, 2237ā2246.
Tockman, M. S., Gupta, P. K., Myers, J. D., et al. (1988) Sensitive and specific monoclonal antibody recognition of human lung cancer antigen on preserved sputum cells: a new approach to early lung cancer detection. J. Clin. Oncol. 6, 1685ā1693.
Payne, P. W., Sebo, T. J., Doudkine, A., et al. (1997) Sputum screening by quantitative microscopy: a re-examination of a portion of the NCI Cooperative Early Lung Cancer Study. Mayo Clin. Proc. 72, 697ā704.
Lam, S., MacAulay, C., Hung, J., LeRiche, J., Profio, A. E., and Palcic, B. (1993) Detection of dysplasia and carcinoma in situ with a lung imaging fluorescence endoscopy (LIFE) device. J. Thoracic Cardiovasc. Surg. 105, 1035ā1040.
Lam, S., Kennedy, T., Unger, M., et al. (1998) Localization of bronchial intraepithelial neoplastic lesions by fluorescence bronchoscopy. Chest 113, 696ā702.
Kurie, J. M., Lee, J. S., Morice, R. C., Walsh, G. L., Khuri, F. R., Broxson, A., et al. (1998) Autofluorescence bronchoscopy in the detection of squamous metaplasia and dysplasia in current and former smokers. J. Natl. Cancer Inst. 90, 991ā995.
Collisharv, N. E. and Lopez, A. D. (1996) The tobacco epidemic: a global public health emergency. Tobacco Alert, World Health Organization, Geneva, Switzerland.
Doll, R. and Hill, A. B. (1954) The mortality of doctors in relation to their smoking habits. A Preliminary report. BMJ 1, 1451ā1455.
Hammond, E. C. and Horn, D. (1954) The relationship between human smoking habits and death rates: a follow-up study of 187 766 men. JAMA 155, 1316ā1328.
Thun, M. J., Day-Lalley, C. A., Calle, E. E., Flanders, W. D., and Heath, C. A. (1995) Excess mortality among cigarette smokers: changes in a 20-year interval. Am. J. Public Health 85, 1223ā1230.
Doll, R., Peto, R., Wheatley, K., Gray, R., and Sutherland, I. (1994) Mortality in relation to smoking: 40 yearsā observations on male British doctors. BMJ 309, 901ā911.
Hirayama, T. (1981) Non-smoking wives of heavy smokers have a higher risk of lung cancer: a study from Japan. BMJ 282, 183ā185.
Trichopoulos, D., Kalandida, A., Sparros, L., and MacMahon, B. (1981) Lung cancer and passive smoking. Int. J. Cancer 23, 803ā807.
Harris, R. E., Zang, E. A., Anderson, J. I., and Wynder, E. L. (1993) Race and sex differences in lung cancer risk associated with cigarette smoking. Int. J. Epidemiol. 22, 592ā599.
Ryberg, D., Hewer, A., Phillips, D. H., and Haugen, A. (1994) Different susceptibility to smoking induced DNA damage among male and female lung cancer patients. Cancer Res. 54, 5801ā5803.
Fielding, J. E. (1985) Smoking: health effects and control. N. Engl. J. Med. 313, 491ā498, 555ā562.
Thun, M. J., Lally, C. A., Flannery, J. T., Calle, E. E., Flanders, W. D., and Heath, C. W. (1997) Cigarette smoking and changes in the histopathology of lung cancer. J. Natl. Cancer Inst. 89, 1580ā1586.
Pershagen, G., Akerblom, G., Axelson, O., et al. (1994) Residential radon exposure and lung cancer in Sweden. N. Engl. J. Med. 330, 159ā164.
Hammond, E. C., Selikoff, I. J., and Seidman, H. (1979) Asbestos exposure, cigarette smoking, and death rates. Ann. NY Acad. Sci. 330, 473ā490.
Hecht, S. S. (1998) Cigarette smoking and cancer, in Environmental and Occupational Medicine, 3rd ed. (Rom, W. N., ed.), Lippincott-Raven, Philadelphia, pp. 1479ā1500.
Spivack, S. D., Fasco, M. J., Walker, V. E., and Kaminsky, L. S. (1997) The molecular epidemiology of lung cancer. Crit. Rev. Toxicol. 27, 319ā365.
Wei, Q., Cheng, L., Hong, W. K., and Spitz, M. R. (1996) Reduced DNA repair capacity in lung cancer patients. Cancer Res. 56, 4103ā4107.
Wuerin, J. and Nurse, P. (1996) Regulating S phase: CDKs, licensing and proteolysis. Cell 85, 785ā787.
Sherr, C. (1996) Cancer cell cycles. Science 274, 1672ā1677.
Hunter, T. and Pines, J. (1994) Cyclins and Cancer II: Cyclin D and CDK inhibitors come of age. Cell 79, 573ā582.
Schaur, E. I., Siriwardana, S., Langan, T. A., and Sciafani, R. A. (1994) Cyclin D1 overexpression vs. retinoblastoma inactivation: implications for growth control evasion in non-small cell and small cell lung cancer. Proc. Natl. Acad. Sci. USA 91, 7827ā7831.
Weintraub, S. J. (1996) Inactivation of tumor suppressor proteins in lung cancer. Am. J. Respir. Cell Mol. Biol. 15, 150ā155.
El-Deiry, W. S., Tokino, T., Velculescu, V. E., et al. (1993) WAF1, a potential mediator of p53 tumor suppression. Cell 75, 817ā825.
Nevins, J. R. (1992) E2F: a link between the Rb tumor suppressor protein and viral oncoproteins. Science 258, 424ā429.
Barak, Y., Juven, T., Haffner, R., and Oren, M. (1993) Mdm2 expression is induced by wild type p53 activity. EMBO J. 12, 461ā468.
Stillman, B. (1996) Cell cycle control of DNA replication. Science 274, 1659ā1663.
Sanders Williams, R., Shohet, R. V., and Stillman, B. (1997) A human protein related to yeast Cdc6p. Proc. Natl. Acad. Sci. USA 94, 142ā147.
Yan, Z., DeGregori, J., Shohet, R., et al. (1998) Cdc6 is regulated by E2F and is essential for DNA replication in mammalian cells. Proc. Natl. Acad. Sci. USA 95, 3603ā3608.
Levine, A. J., Momand, J., and Finlay, C. A. (1991) The p53 tumour suppressor gene. Nature 351, 453ā456.
Greenblatt, M. S., Bennett, W. P., Hollstein, M., and Harris, C. C. (1994) Mutations in the p53 tumor suppressor gene: clues to cancer etiology and molecular pathogenesis. Cancer Res. 54, 4855ā4878.
Prives, C. (1998) Signaling to p53: breaking the MDM2-p53 circuit. Cell 95, 1437ā1443.
Weinberg, R, A. (1991) Tumor suppressor genes. Science 254, 1138ā1146.
Knudson, A. G. (1993) Antioncogenes and human cancer. Proc. Natl. Acad. Sci. USA 90, 10914ā10921.
Tchou, W. W., Rom, W. N., and Tchou-Wong, K.-M. (1996) Novel form of p21 WAF1/C1P1/SC11 protein in phorbol ester-induced G2/M arrest. J. Biol. Chem. 271, 29556ā29560.
Ramet, M., Casten, K., Jarvinen, K., et al. (1996) p53 protein expression is correlated with benzo[a]pyrene-DNA adducts in carcinoma cell lines. Carcinogenesis 16, 2117ā2124.
Denissenko, M. F., Pao, A., Tang, M., and Pfeifer, G. P. (1996) Preferential formation of benzo[a] pyrene adducts at lung cancer mutational hotspots in p53. Science 274, 430ā432.
Denissenko, M. F., Chen, J. Y., Tang, M. S., and Pfeifer, G. P. (1997) Cytosine methylation determines hot spots of DNA damage in the human p53 gene. Proc. Natl. Acad. Sci. USA 94, 3893ā3898.
Chen, J. X., Zheng, Y., West, M., and Tang, M. (1998) Carcinogens preferentially bind at methylated CpG in the p53 mutational hot spots. Cancer Res. 58, 2070ā2075.
Waga, S., Hannon, G. J., Beach, D., and Stillman, B. (1994) The p21 inhibitor of cyclin-dependent kinases controls DNA replication by interaction with PCNA. Nature 369, 574ā578.
Smith, M. L., Chen, I.-T., Zhan, Q., et al. (1994) Interaction of the p53-regulated protein Gadd45 with proliferating cell nuclear antigen. Science 266, 1376ā1380.
Zambetti, G. and Levine, A. J. (1993) A comparison of the biological activities of wild-type and mutant p53. FASEB J. 7, 855ā865.
Werner, H., Karnieli, E., Rauscher, III F. J., and LeRoith, D. (1996) Wild-type and mutant p53 differentially regulate transcription of the insulin-like growth factor I receptor gene. Proc. Natl. Acad. Sci. USA 93, 8318ā8323.
Jiang, Y., Rom, W. N,, Yie, T. A., Chi, C., and Tchou-Wong, K. M. (1999) Induction of tumor suppression and glandular differentiation of A549 lung carcinoma cells by dominant negative IGF-I receptor. Oncogene 18, 6071ā6077.
Kamb, A., Gruis, N. A., Weaver-Feldhaus, J., et al. (1994) A cell cycle regulator potentially involved in genesis of many tumor types. Science 264, 436ā440.
Cairns, P., Polascik, T. J., Eby, Y., et al. (1995) Frequency of homozygous deletion at p16/CDKN2 in primary human tumors. Nat. Genet. 11, 210ā212.
Okamoto, A., Hussain, S. P., Hagiwara, K., et al. (1995) Mutations in the p16INK4/MTS1/CDKN2, p15INK4B/MTS2, and p18 genes in primary and metastatic lung cancer. Cancer Res. 55, 1448ā1451.
Rusin, M. R., Okamoto, A., Chorazy, M., et al. (1996) Intragenic mutations of the p16INK4, p15INK4B and p18 genes in primary non-small-cell lung cancers. Int. J. Cancer 65, 734ā739.
Belinsky, S. A., Nikula, K. J., Palmisano, W. A., Michels, R., Saccomanno, G., Gabrielson, E., Baylin, S. B., and Herman, J. G. (1998) Aberrant methylation of p16INK4a is an early event in lung cancer and a potential biomarker for early diagnosis. Proc. Natl. Acad. Sci. USA 95, 11891ā11896.
Michalides, R. J. A. M. (1998) Deregulation of the cell cycle in lung cancer, in Lung Biology in Health and Disease (Brambilla, C. and Brambilla, E., eds.), Marcell Dekker Inc., New York, pp. 211ā225.
Haber, D. A. (1997) Splicing into senescence: the curious case p16 and p19ARF. Cell 91, 555ā558.
Harbour, J. W., Lai, S. L., Whang-Peng, J., et al. (1988) Abnormalities in structure and expression of the human retinoblastoma gene in SCLC. Science 241, 353ā357.
Shapiro, G. I., Edwards, C. D., Kobzik, L., et al. (1995) Reciprocal Rb inactivation and p16INK4 expression in primary lung cancers and cell lines. Cancer Res. 55, 505ā509.
Kelley, M. J., Nakagawa, K., Steinberg, S. M., Mulshine, J. L., Kamb, A., and Johnson, B. E. (1995) Differential inactivation of CDKN2 and Rb protein in non-small-cell and small-cell lung cancer cell lines. J. Natl. Cancer Inst. 87, 756ā761.
Gorgoulis, V. G., Zacharatos, P., Kotsinas, A., et al. (1998) Alterations of the p16-pRb pathway and the chromosome locus 9p21ā22 in non-small-cell lung carcinomas. Am. J. Path. 153, 1749ā1765.
Bates, S., Phillips, A., Clarke, P., et al. (1998) p14ARF links the tumour suppressors RB and p53. Nature 395, 124ā125.
Zindy, F., Eischen, C. M., Randle, D. H., Kamijo, T., Cleveland, J. L., Sherr, C. J., and Roussel, M. F. (1998) Myc signaling via the ARF tumor suppressor regulates p53-dependent apoptosis and immortalization. Genes Dev. 12, 2424ā2433.
Pomerantz, J., Schreiber-Angus, N., Liegeois, N. J., et al. (1998) The INK4a tumor suppressor gene product, p19ARF, interacts with MDM2 and neutralizes MDM2ās inhibition of p53. Cell 92, 713ā723.
Kamijo, T., Weber, J. D., Zambetti, G., Zindy, F., Roussel, M. F., and Sherr, C. J. (1998) Functional and physical interactions of the ARF tumor suppressor with p53 and Mdm2. Proc. Natl. Acad. Sci. USA 95, 8292ā8297.
Zhang, Y. and Xiong, Y. (1999) Mutations in human ARF exon 2 disrupt its nucleolar localization and impair its ability to block nuclear export of MDM2 and p53. Mol. Cell 3, 579ā591.
Gazzeri, S., Della Valle, V., Chaussade, L., Brambilla, C., Larsen, C. J., and Brambilla, E. (1998) The human p19INK4a gene is frequently lost in small cell lung cancer. Cancer Res. 58, 3926ā3931.
Hannon, G. J. and Beach, D. (1994) p15INK4B is a potential effector of TGF-Ī²-induced cell cycle arrest. Nature 371, 257ā261.
Kim, S. J., Wagner, S., Lin, F., OāReilly, M. A., Robbins, P. D., and Green, M. R. (1992) Retinoblastoma gene product activates expression of the human TGF-Ī²2 gene through transscription factor ATF-2. Nature 358, 331ā334.
Li, C.-Y., Suardet, L., and Little, J. R. (1995) Potential role of WAF1/Cip/p21 as a mediator of TGF-Ī² cytoinhibitory effect. J. Biol. Chem. 270, 4971ā4974.
Iavarone, A. and Massague, J. (1997) Repression of the CDK activator Cdc 25A and cell-cycle arrest by cytokine TGF-Ī² in cells lacking the CDK inhibitor p15. Nature 387, 417ā421.
Zhang, H. S., Postigo, A. A., and Dean, D. C. (1999) Active transcriptional repression by the Rb-E2F complex mediates G1 arrest triggered by p16INK4a, TGFĪ², and contact inhibition. Cell 97, 53ā61.
Mills, N. E., Fishman, C. L., Rom, W. N., et al. (1995) Increased prevalence of K-ras oncogene mutations in lung adenocarcinoma. Cancer Res. 55, 1444ā1447.
Mills, N. E., Fishman, C. L., Scholes, J., Anderson, S. E., Rom, W. N., and Jacobson, D. R. (1995) Detection of K-ras oncogene mutations in bronchoalveolar lavage fluid as a diagnostic test for lung cancer. J. Natl. Cancer Inst. 87, 1056ā1060.
Slebos, R. J. C., Kibbelaar, R. E., Dalesio, O., et al. (1990) K-ras oncogene activation as a prognostic marker in adenocarcinoma of the lung. N. Engl. J. Med. 9, 561ā565.
Zhang, Y., Mukhopadhyay, T., Donehower, L. A., Georges, R. N., and Roth, J. A. (1993) Retroviral vector-mediated transduction of K-ras antisense RNA into human lung cancer cells inhibits expression of the malignant phenotype. Hum. Gene Ther. 4, 451ā460.
Moodie, S. A., Willumsen, B. M., Weber, M. J., and Wolfman, A. (1993) Complexes of ras-GTP with raf-1 and mitogen-activated protein kinase kinase. Science 260, 1658ā1661.
Li, Z. H., Zheng, J., Weiss, L. M., and Shibata, D. (1994) K-ras and p53 mutations occur very early in adenocarcinoma of the lung. Am. J. Pathol. 144, 303ā309.
Agarwal, M. L., Taylor, W. R., Chernov, M. V., Chernova, O. B., and Stark, G. R. (1998) The p53 network. J. Biol. Chem. 273, 1ā4.
Leone, G., DeGregori, J., Sears, R., Jakoi, L., and Nevins, J. R. (1997) Myc and ras collaborate in inducing accumulation of active cyclin E/Cdk2 and E2F. Nature 387, 422ā426.
Peeper, D. S., Upton, T. M., Ladha, M., et al. (1997) Ras signaling linked to the cell-cycle machinery by the retinoblastoma protein. Nature 386, 177ā181.
Sears, R., Leone, G., DeGregori, J., and Nevins, J. R. (1999) Ras enhances myc protein stability. Mol. Cell 3, 169ā179.
Serrano, M., Gomez-Lahoz, E., DePinho, R. A., Beach, D., and Bar Sagi, D. (1995) Inhibition of ras-induced proliferation and cellular transformation by p16ink4. Science 267, 249ā252.
Olson, M. F., Peterson, H. F., and Marshall, C. F. (1998) Signals from Ras and Rho GTPases interact to regulate expression of p21WA F1/C1P1. Nature 394, 295ā299.
Palmero, I., Pantoja, C., and Serrano, M. (1998) p19ARF links the tumour suppressor p53 to ras. Nature 395, 125ā126.
Kamijo, T., Bodner, S., van de Kamp, E., Randle, D. H., and Sherr, C. J. (1999) Tumor spectrum in ARF-deficient mice. Cancer Res. 59, 2217ā2222.
Galaktionov, K., Chen, X., and Beach, D. (1996) Cdc25 cell-cycle phosphatase as a target of c-myc. Nature 382, 511ā517.
Hunter, T. (1997) Oncoprotein networks. Cell 88, 333ā346.
Lee, T. C. and Ziff, E. B. (1999) Mxi1 is a repressor of the c-myc promoter and reverses activation by USF. J. Biol. Chem. 274, 595ā606.
Lee, T. C., Li, L., Philipson, L., and Ziff, E. B. (1997) Myc represses transcription of the growth arrest gene gas1. Proc. Natl. Acad. Sci. USA 94, 12886ā12891.
Marhin, W. W., Chen, S., Facchini, L. M., Fornace, A. J. Jr., and Penn, L. Z. (1997) Myc represses the growth arrest gene gadd45. Oncogene 14, 2825ā2834.
Del Sal, G., Ruaro, E. M., Utrera, R., Cole, C. N., Levine, A. J., and Schneider, C. (1995) Gas1-induced growth suppression requires a transactivation-independent p53 function. Mol. Cell. Biol. 15, 7152ā7160.
Viallet, J. and Minna, J. (1990) Dominant oncogenes and tumor suppressor genes in the pathogenesis of human lung cancer. Am. J. Respir. Cell Mol. Biol. 2, 225ā232.
Broers, J. L. V., Viallet, J., Jensen, S. M., Pass, H., Travis, W. D., Minna, J. D., and Linnoila, R. I. (1993) Expression of c-myc in progenitor cells of the bronchopulmonary epithelium and in a large number of non-small cell lung cancers. Am. J. Respir. Cell Mol. Biol. 9, 33ā43.
Gazzeri, S., Brambilla, E., Caron de Fromentel, C., Bouyer, V., Moro, D., Perron, P., et al. (1994) p53 genetic abnormalities and myc activation in human lung carcinoma. Int. J. Cancer 58, 24ā32.
Franklin, W. A., Gazdar, A. F., Haney, J., et al. (1997) Widely dispersed p53 mutation in respiratory epithelium: a novel mechanism for field carcinogenesis. J. Clin. Invest. 100, 2133ā2137.
Auerbach, O. C., Hammond, C., and Garfinkel, L. (1979) Changes in bronchial epithelium in relation to cigarette smoking, 1955ā1960 vs 1970ā1977. N. Engl. J. Med. 300, 381ā386.
Saccomanno, G., Archer, V. E., Auerbach, O., Saunders, R. P., and Brennan, L. U. (1974) Development of carcinoma of the lung as reflected in exfoliated cells. Cancer 33, 256ā270.
Risse, E. K. J., Vooijs, G. P., and vanāt Hof, M. A. (1988) Diagnostic significance ofā severe dysplasiaā in sputum cytology. Acta Cytol. 32, 629ā634.
Keith, R. L., Varella-Garcia, M., Gemmill, R. M., et al. (1998) Morphologic and genetic abnormalities in the bronchial epithelium of high risk smokers. Am. J. Respir. Crit. Care Med. 157, 692A.
van Steensel, B. and de Lange, T. (1998) Control of telomere length by the human telomeric protein TRF1. Nature 385, 740ā743.
Hayflick, L. and Moorhead, P. S. (1961) The serial cultivation of human diploid cells strains. Exp. Cell Res. 25, 585ā621.
Chin, L., Artandi, S. E., Shen, Q., Tam, A., Lee, S. L., Gottlieb, G. J., et al. (1999) p53 deficiency rescues the adverse effects of telomere loss and cooperates with telomere dysfunction to accelerate carcinogenesis. Cell 97, 527ā538.
Bodnar, A. G., Ouellette, M., Frolkis, M., Holt, S. E., Chiu, C. P., Morin, G. B., et al. (1998) Extension of life-span by introduction of telomerase into normal human cells. Science 279, 349ā352.
Kiyono, T., Foster, S. A., Koop, J. I., McDougall, J. K., Galloway, D. A., and Klingelhutz, A. J. (1998) Both Rb/p16INK4a inactivation and telomerase activity are required to immortalize human epithelial cells. Nature 396, 84ā88.
Greenberg, R. A., Chin, L., Femino, A., Lee, K. H., Gottlieb, G. J., Singer, R. H., et al. (1999) Short dysfunctional telomere impair tumorigenesis in the INK4aĪ2/3 cancer-prone mouse. Cell 97, 515ā525.
Hiyama, K., Hiyama, E., Ishioka, S., Yamakido, M., Inai, K., Gazdar, A. F., et al. (1995) Telomerase activity in small-cell and non-small-cell lung cancers. J. Natl. Cancer Inst. 87, 895ā902.
Albanell, J., Lonardo, F., Rusch, V., Engelhardt, M., Langenfeld, J., Han, W., et al. (1997) High telomerase activity in primary lung cancers: association with increased cell proliferation rates and advanced pathologic stage. J. Natl. Cancer Inst. 89, 1609ā1615.
Yahata, N., Ohyashiki, K., Ohyashiki, J. H., et al. (1998) Telomerase activity in lung cancer cells obtained from bronchial washings. J. Natl. Cancer Inst. 90, 684ā690.
Arai, T., Yasuda, Y., Takaya, T., Ito, Y., Hayakawa, K., Toshima, S., et al. (1998) Application of telomerase activity for screening of primary lung cancer in broncho-alveolar lavage fluid. Oncol. Reports 5, 405ā408.
Yashima, K., Litzky, L. A., Kaiser, L., et al. (1997) Telomerase expression in respiratory epithelium during the multistage pathogenesis of lung carcinomas. Cancer Res. 57, 2373ā2377.
Folkman, J. (1995) Angiogenesis in cancer, vascular, rheumatoid, and other disease. Nature Med. 1, 27ā31.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
Ā© 2003 Humana Press Inc.
About this protocol
Cite this protocol
Rom, W.N., Tchou-Wong, KM. (2003). Molecular and Genetic Aspects of Lung Cancer. In: Driscoll, B. (eds) Lung Cancer. Methods in Molecular Medicineā¢, vol 75. Humana Press, Totowa, NJ. https://doi.org/10.1385/1-59259-324-0:03
Download citation
DOI: https://doi.org/10.1385/1-59259-324-0:03
Publisher Name: Humana Press, Totowa, NJ
Print ISBN: 978-0-89603-920-9
Online ISBN: 978-1-59259-324-8
eBook Packages: Springer Protocols